They conducted a population-based retrospective cohort study of 3,811 PDAC patients with preexisting diabetes mellitus (DM), diagnosed with PDAC within the VHA between 1998 and 2013. As per outcomes, metformin use did not affect survival in PDAC patients, however, non-Hispanic white patients who were metformin naïve at the time of PDAC diagnosis appeared to gain a survival benefit. Read more . . .
Researchers investigated how metformin use affects the survival of African American patients with pancreatic ductal adenocarcinoma (PDAC) via analyzing data from the United States Veterans Health Administration (VHA).